Relations between the renal hypertension which minded renin-angiotensin system and the renal failure

慢性肾功能衰竭的病例最近在像人类患者这样的小动物诊所中有所增加。因此进行了诊断和治疗的方法学研究，但尚未提出肾性高血压的详细描述。因此，我们在此报告了肾脏疾病在慢性肾功能衰竭猫模型肾性高血压发病机制中的可能作用，该遥测系统允许连续24小时监测清醒的无拘束动物的血压，重点关注血压和肾素-血管紧张素-阿尔索酮系统中的某些参数。此外，我们将描述血管紧张素转换酶抑制剂在目前慢性肾功能衰竭动物模型中对肾性高血压的影响。[结果]5只猫的肾功能评估显示，与…相比，慢性肾功能衰竭术后5只猫的BUN和血清肌酐水平显著升高(P<0.05)，Ccr显著降低(P&lt；0.05)。更多的是术前价值。此外，术后的收缩压、平均压和舒张压均显著高于对照组(p&lt；0.05)。血浆肾素活性、血管紧张素I(Ang-I)、血管紧张素II(Ang-II)和ALD均较术前显著升高(P<0.05)。在慢性肾功能衰竭的动物模型中，与治疗前相比，盐酸贝那普利在治疗期间使收缩压、平均压和舒张压显著下降(p&lt；0.05)。停药后，压力几乎恢复到治疗前的水平。同时，ACE-I导致血浆血管紧张素II和ALD水平在治疗期间显著下降(p&lt；0.05)，并在停药后维持在较低水平。另一方面，在观察期间，ACE-I并没有改变血浆肾素活性和血管紧张素-I(Ang-I)水平。肾功能指标(BUN、Cr、Ccr)在应用ACE-I治疗前后无明显变化。本研究建立的慢性肾功能衰竭动物模型表现为肾性高血压，而ACE-I可明显逆转这一变化，而不加重肾功能紊乱。因此，高血压的治疗是慢性肾功能衰竭病情加重的因素之一，可以阻止慢性肾功能衰竭的进展，而ACE-I对未来的小动物高血压患者有很大的好处。较少

The cases of chronic renal failure have recently grown in small animal clinics like human patients. The methodological studies of diagnosis and therapy have been thus conducted but no detailed description of renal hypertension has been presented. Therefore, we report herein the possible contribution of renal disorders to the pathogenesis of renal hypertension in cat models of chronic renal failure using a telemetry system that allows monitoring the blood pressure in awake unrestrained animals for 24 consecutive hours, focusing on the blood pressure and certain parameters in the renin-angiotensin-alsosterone system. Moreover, we will describe the effect of an angiotensin converting enzyme inhibitor on renal hypertension in the present animal models of chronic renal failure. [Results] The evaluation of renal function in the 5 cats demonstrated significantly elevated BUN and serum Cr levels (p<0.05) and lowered CCr (p<0.05) after the operation for chronic renal failure when compared with … More the preoperative values. In addition, the systolic, mean and diastolic pressures after the operation were all significantly higher than the control values (p<0.05). Plasma renin activity, angiotensin I (ANG-I), angiotensin II (ANG-II) and ALD were all significantly elevated after the operation when compared with the preoperative values (p<0.05). In the animal models of chronic renal failure, benazepryl hydrochloride produced a significant fall in systolic, mean and diastolic pressures during the treatment period when compared with the pre-treatment levels (p<0.05). The pressures returned to almost the same as the pre-treatment levels after the discontinuation of the drug. At the same time, the ACE-I led to the significant decreases in plasma angiotensin II and ALD during the treatment period (p<0.05), followed by the sustained low levels after the discontinuation of the drug. On the other hand, the ACE-I did not alter either plasma renin activity or angiotensin I (ANG-I) level during the observation period. The indices of renal function (BUN, Cr, CCr) showed no significant change before, during and after the treatment with the ACE-I.In this study, the animal models of chronic renal failure demonstrated renal hypertension, which was obviously reversed by the ACE-I without advancing the renal disorder. It has been therefore suggested that the management of high blood pressure, which is one of the factors aggravating the condition of chronic renal failure, could stop the progression of chronic renal failure and ACE-I's are of great benefit to small animal patients with hypertension in future. Less